.28 Jan 2021 08:17
Nothing to say but slow....anyway another big name partnership isn't a bad thing
No mention of LFT or any holding statement but end note is interesting, 9 months we've figured a name for our product hopefully we can start validation soon ;)
In all seriousness, expecting a separate announcement
"Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Company is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDXTM SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMSTM SARS-CoV-2 Assay in partnership with Adeptrix Inc."